Adenovirus vector
AssigneesFuso Pharmaceutical Industries, Ltd., Hiroyuki Mizuguchi, Takao Hayakawa, Fuminori Sakurai
InventorsHiroyuki Mizuguchi, Takao Hayakawa, Fuminori Sakurai
Life of this patent
Estimating the term…
Abstract
This invention relates to an adenovirus vector having excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells. This adenovirus vector derives from the adenovirus type 35 genome by at least partial or total deletion of the E1 region therefrom. The adenovirus vector according to this invention has excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells, ES cells, pluripotent stem cells, blood stem cells, and tissue stem cells.
Claims5
An adenovirus type 35 vector, comprising an adenovirus type 35 genome from which there are deleted (A) a segment of the E1 region, wherein the segment consists of nucleotides 367 to 2,917 and (B) a segment of the E3 region, wherein the segment consists of nucleotides 27,760 to 29,732.
Dependencies are inferred from the claim text.